“If you look at the example of COVID, everybody is in awe of the ability of companies, institutions and regulators to work at the same time, rather than sequentially, to produce vaccines. However, making sure everybody that needs those vaccines can get hold of them is an interesting practical challenge. That dilemma does not just apply to COVID. There are many medicines where a disconnect exists between those patients who would like to get it, and those who are actually able to gain access.”
Shaun Chilton, CEO, Clinigen Group